Technical Analysis for ALGS - Aligos Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | N/A |
| Historical ALGS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing High | Bullish | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| New 52 Week Closing High | Bullish | 0.20% | |
| New 52 Week Closing High | Bullish | 1.07% | |
| New 52 Week Closing Low | Bearish | 14.39% | |
| Hot IPO Pullback | Bullish Swing Setup | 14.39% | |
| New 52 Week Low | Weakness | 14.39% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Down 2 % | 3 days ago | |
| Reversed from Up | 3 days ago | |
| Gap Up Closed | 3 days ago | |
| Down 1% | 3 days ago | |
| Up 2% | 3 days ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
- Sector: Healthcare
- Industry: Biotechnology
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
Medicine Clinical Medicine Drug Development Hepatitis Infectious Causes Of Cancer Non Alcoholic Fatty Liver Disease Healthcare Associated Infections Steatohepatitis Liver Diseases Viral Diseases Liver Disease Viral Infections
Medicine Clinical Medicine Drug Development Hepatitis Infectious Causes Of Cancer Non Alcoholic Fatty Liver Disease Healthcare Associated Infections Steatohepatitis Liver Diseases Viral Diseases Liver Disease Viral Infections
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 17.5 |
| 52 Week Low | 12.82 |
| Average Volume | 367,228 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 0.00 |
| 10-Day Moving Average | 0.00 |
| Average True Range | 0.00 |
| ADX | 0.0 |
| +DI | 0.00 |
| -DI | 0.00 |
| Chandelier Exit (Long, 3 ATRs ) | N/A |
| Chandelier Exit (Short, 3 ATRs ) | N/A |
| Upper Bollinger Band | 0.00 |
| Lower Bollinger Band | 0.00 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.00 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.00 |
| MACD Histogram | 0.0 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 16.24 | ||||
| Resistance 3 (R3) | 16.21 | 15.79 | 16.05 | ||
| Resistance 2 (R2) | 15.79 | 15.50 | 15.81 | 15.99 | |
| Resistance 1 (R1) | 15.45 | 15.32 | 15.24 | 15.48 | 15.92 |
| Pivot Point | 15.03 | 15.03 | 14.93 | 15.05 | 15.03 |
| Support 1 (S1) | 14.69 | 14.74 | 14.48 | 14.72 | 14.28 |
| Support 2 (S2) | 14.27 | 14.56 | 14.29 | 14.21 | |
| Support 3 (S3) | 13.93 | 14.27 | 14.15 | ||
| Support 4 (S4) | 13.96 |
